Study guide
7.2 Cystic Fibrosis Pathogens and Quantitative Reporting
ASCP Microbiology Technologist M ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current M(ASCP) Exam Facts 1.2 CAT, Scoring, Retakes, and CMP 1.3 Eligibility Routes and Clinical Experience
2 Preanalytic: Collection and Transport
2.1 Patient Identification and Specimen Labeling 2.2 Specimen Collection, Sterile Technique, and Blood Cultures 2.3 Transport Devices, Atmosphere, Time, and Temperature
3 Preanalytic: Processing, Media, and Incubation
3.1 Prioritization, Rejection, and Specimen Preparation 3.2 Media Types, Components, and Selection 3.3 Inoculation, Incubation Conditions, and Slide Preparation
4 Preanalytic: Stains
4.1 Gram Stain: Procedure, Principle, and Interpretation 4.2 Acid-Fast and Modified Acid-Fast Stains 4.3 KOH, Calcofluor-White, Trichrome, Giemsa, and Acridine Orange
5 Bacteriology: Blood and Bone Marrow
5.1 Blood Culture Systems and Rapid Identification 5.2 Bloodstream Pathogens and Skin Flora Significance 5.3 Endocarditis, Bone Marrow Pathogens, and Pathogenicity
6 Bacteriology: CSF and Sterile Body Fluids
6.1 CSF Sources and Acute Meningitis Pathogens 6.2 Shunt Infections, CSF Correlates, Antigen and Molecular Methods 6.3 Sterile Body Fluids: Pathogens, Flora, and Molecular Methods
7 Bacteriology: Respiratory Tract
7.1 Lower Respiratory Specimens, CAP, and HAP Pathogens 7.2 Cystic Fibrosis Pathogens and Quantitative Reporting 7.3 Upper Respiratory: Pharyngitis, Otitis, Sinusitis, Antigen/Molecular
8 Bacteriology: Gastrointestinal Tract
8.1 Enteric Pathogens: Culture and Colony Morphology 8.2 Clostridioides difficile, Shiga Toxin, and Serotyping 8.3 Helicobacter pylori Detection and GI Pathogenicity
9 Bacteriology: Skin, Soft Tissue, and Bone
9.1 Skin, Soft Tissue, and Bone Pathogens 9.2 Bite Wounds and Zoonotic Infections 9.3 SST Pathogenicity and Virulence Mechanisms
10 Bacteriology: Genital Tract and Urine
10.1 Genital Flora and Vaginitis Pathogens 10.2 Neisseria gonorrhoeae, Chlamydia trachomatis, GBS, and Mycoplasma 10.3 Urinary Pathogens, Colony Counts, and Urinalysis Correlation
11 Bacteriology: Identification Methods
11.1 Colony Morphology and Rapid Presumptive Tests 11.2 Conventional Biochemicals and Commercial Kits 11.3 Automated Methods, MALDI-TOF MS, Molecular, and 16S Sequencing
12 Bacteriology: Antimicrobial Susceptibility and Resistance
12.1 Microbroth Dilution, Disk Diffusion, and Gradient Diffusion 12.2 Phenotypic Detection of Resistance 12.3 Antibiotic Classes, Intrinsic Resistance, and Genetic Markers
13 Bacteriology: Resistance Screening and Select Agents
13.1 MRSA/MSSA, VRE, ESBL/CRE Screening 13.2 BSL-3 Pathogens and Select-Agent Presumptive Identification 13.3 Laboratory Response Network and Select-Agent Pathogenicity
14 Mycobacteriology and Nocardia
14.1 Specimens, Major Pathogens, and Disease States 14.2 Acid-Fast Reaction, Colony Morphology, and Growth Characteristics 14.3 Identification Methods, Direct Molecular Detection, and TB Therapy
15 Virology
15.1 Respiratory, Vesicle, Meningitis, and GI Viruses 15.2 Hepatitis, HIV, and Immunocompromised-Host Viruses 15.3 Direct Detection Methods and HPV Cervical Screening
16 Parasitology
16.1 Blood, Tissue, and Brain Protozoa 16.2 Intestinal/Urogenital Protozoa and Helminths 16.3 Microscopy, Antigen/Molecular Detection, Insects and Arthropods
17 Mycology
17.1 Yeasts: Candida, Cryptococcus, and Malassezia 17.2 Dimorphic Fungi and Dermatophytes 17.3 Mucorales, Hyaline Molds, Pneumocystis, and Identification Methods
18 Serology
18.1 Immunoglobulin Response and Antigen-Antibody Methods 18.2 Viral Serodiagnosis: Hepatitis, EBV, HIV, CMV, Rubella, Measles 18.3 Treponema, Borrelia, and TB Infection Serodiagnosis
19 Laboratory Operations: Postanalytic Procedures and Quality
19.1 Documentation, Critical Values, Corrected Reports, and Public Health 19.2 Quality Control, Root-Cause Analysis, and POCT 19.3 Proficiency Testing, Competency, and Accreditation
20 Laboratory Operations: Safety, Mathematics, and Instrumentation
20.1 Biosafety, PPE, Bloodborne Pathogens, and SDS 20.2 Emergencies and Packaging/Transportation of Specimens 20.3 Laboratory Mathematics and Instrumentation
7.2 Cystic Fibrosis Pathogens and Quantitative Reporting
Key Takeaways Explain This Topic AI
Typical interpretive ranges used in clinical microbiology are about 10^3 CFU/mL for protected brush, 10^4 CFU/mL for BAL, and 10^5 CFU/mL for endotracheal aspirate; laboratories report from validated procedures, not from a memorized universal cutoff.
Cystic fibrosis pathogens on the M outline are Staphylococcus aureus, Pseudomonas spp., Haemophilus influenzae, and Burkholderia cepacia complex.
Use mannitol salt agar for S. aureus and OFPBL, BCSA, or PC agar for B. cepacia complex so slow or selective organisms are not buried in mucoid growth.
Mucoid P. aeruginosa overproduces alginate biofilm; B. cepacia complex requires infection-control isolation because of clinic transmission and cepacia syndrome.
Inspect chocolate agar (often with bacitracin), look under mucoid colonies, and watch for S. aureus small-colony variants so swarming Proteus or mucoid Pseudomonas cannot hide H. influenzae or persistent staphylococci.
Last updated: August 2026
7.2 Cystic Fibrosis Pathogens and Quantitative Reporting
Quick Answer: Protected-brush cultures are often interpreted around 10^3 CFU/mL , BAL around 10^4 CFU/mL , and endotracheal aspirates around 10^5 CFU/mL —typical ranges used in clinical microbiology, with each laboratory following its validated procedure. Cystic fibrosis plates must recover S. aureus (mannitol salt), Pseudomonas spp., H. influenzae (chocolate, not hidden under mucoid growth), and B. cepacia complex (OFPBL, BCSA, or PC agar). Mucoid P. aeruginosa alginate and B. cepacia isolation are infection-control and prognostic facts.
Outline II.D.2 asks for the significance of quantitative and semiquantitative reporting . Outline II.D.4.c names the cystic fibrosis pathogen set. Together they test whether you can turn a number on a report into a clinical meaning and whether you can find a slow, selective, or hidden organism in a specimen that looks like glue.
Why counts matter
The lower airway is not sterile once a tube or chronic disease is present. A single colony of P. aeruginosa from a protected brush does not mean the same thing as a lawn from an endotracheal aspirate. Quantitative culture estimates CFU per milliliter of specimen. Semiquantitative culture uses 1+ to 4+ or rare/few/moderate/many after a standardized streak. Both exist to answer one question: is this organism present at a burden that correlates with pneumonia, or is it colonizing the tube and mouth?
Typical interpretive ranges used in clinical microbiology practice (and the numbers you should recognize on M) are:
Specimen Typical significance threshold Why the number sits there
Protected specimen brush About 10^3 CFU/mL Tiny, low-contamination sample; a lower count is already a lot of bacteria in a small volume
BAL About 10^4 CFU/mL Larger alveolar sample with some carryover; 10^4 is a widely cited VAP breakpoint
Endotracheal aspirate About 10^5 CFU/mL Heavily colonized tube; a higher bar reduces false-positive “VAP” from biofilm
Expectorated sputum Often semiquantitative rather than strict CFU/mL Contamination is so common that quality Gram stain plus predominant growth is the practical filter
These are typical ranges , not a single CLIA-mandated universal cutoff. Laboratories validate dilution schemes, loop volumes, and reporting comments. If the stem says “the laboratory’s validated BAL threshold is 10^4 CFU/mL,” honor that SOP. If the stem gives no SOP, the 10^3 / 10^4 / 10^5 ladder is the pattern to apply.
Correlate the count with the Gram stain. Intracellular organisms in neutrophils on a cytocentrifuged BAL smear support infection even before colonies mature. A 10^5 Candida count from ETA in a patient without yeast on stain is more often colonization. Quantitation without morphology is incomplete.
Semiquantitative reporting still has meaning. Heavy, predominant growth of one morphotype from a quality sputum is more significant than mixed 1+ oral flora. “Rare S. aureus ” from a dirty sputum is not the same report as “4+ mucoid P. aeruginosa ” from a CF patient who is declining.
Cystic fibrosis pathogens on the M outline
CF sputum is thick, chronically infected, and microbiologically crowded. The outline’s major pathogens are:
Organism Why it matters in CF Bench priorities
Staphylococcus aureus (MSSA and MRSA) Early and persistent colonizer; small-colony variants hide Mannitol salt agar; look for tiny SCVs
Pseudomonas spp. , especially mucoid P. aeruginosa Alginate biofilm, accelerated lung decline Cetrimide or other Pseudomonas-selective agar; do not stop at the first nonmucoid colony
Haemophilus influenzae Common, fastidious, easily overgrown Chocolate agar, CO2, bacitracin disk; inspect under mucoid film
Burkholderia cepacia complex Clinic transmission, intrinsic resistance, cepacia syndrome OFPBL, BCSA, or PC agar; isolate the patient
Other organisms ( Achromobacter , nontuberculous mycobacteria, Aspergillus ) appear in real CF care. They are not the M outline’s named set. Study the four that are listed, then use selective media so those four cannot be missed.
Selective media and a CF workup that actually finds the organism
A CF culture is not a community sputum planted on blood, chocolate, and MacConkey for 24 hours. Homogenization (often DTT or another liquefying agent), a battery of selective plates, and prolonged incubation (commonly 3–5 days, with some plates held longer per SOP) are the difference between “no Burkholderia ” and a missed complex member.
Mannitol salt agar (7.5% NaCl, mannitol, phenol red) selects staphylococci. S. aureus usually ferments mannitol (yellow). MRSA still needs a cefoxitin screen, chromogenic MRSA agar, or mecA testing; MSA alone does not equal methicillin resistance. The plate’s job is to pull staphylococci out of a Pseudomonas lawn.
B. cepacia selective media are named on purpose:
OFPBL — oxidation-fermentation polymyxin-bacitracin-lactose agar. Many B. cepacia complex isolates oxidize lactose and appear yellow.
BCSA — Burkholderia cepacia selective agar, more inhibitory and often more sensitive than older PC formulations.
PC agar — Pseudomonas cepacia agar, the historic name; still used in some procedures.
Growth on these media is presumptive , not a final identification. Confirm with biochemical panels, MALDI-TOF (with a database that distinguishes complex members when possible), or molecular methods. Misidentifying B. cepacia complex as Pseudomonas or Burkholderia gladioli has infection-control consequences.
Chocolate agar remains mandatory because H. influenzae will not compete on MacConkey and may not grow on sheep blood without V factor. A bacitracin disk on chocolate suppresses some Gram-positive flora and creates a window where Haemophilus can satellite. If the plate is a mucoid Pseudomonas smear, look at the edge and underneath . Lift or subculture the mucoid film. A workup that reports only the swarm is an incomplete CF culture.
Typical log10 CFU/mL interpretive thresholds used in clinical microbiology practice
Loading diagram... Quantitative thresholds and cystic fibrosis selective workup
Mucoid Pseudomonas and alginate
In CF airways, P. aeruginosa often switches to a mucoid phenotype. The slime is alginate , an exopolysaccharide overproduced after regulatory mutations (classically mucA ). Alginate is not the same as the pneumococcal capsule, but it plays a similar antiphagocytic, biofilm-building role. Mucoid colonies look wet and runny, can drip onto neighboring streaks, and may be harder to pick for identification or susceptibility testing. Convert a mucoid isolate to a workable inoculum per SOP; do not skip AST because the colony is ugly.
Mucoid conversion correlates with chronic infection and poorer lung function. Nonmucoid P. aeruginosa can still be present on the same plate. Report both phenotypes when the procedure calls for it. Oxidase, pigment, grape odor, and growth at 42 °C still support P. aeruginosa , but pigment may be muted in mucoid strains.
Burkholderia cepacia complex and infection control
B. cepacia complex is a group of related species (historically genomovars; B. cenocepacia and B. multivorans are frequent in CF). Two exam-level facts dominate:
Infection control. The complex spreads in CF clinics and social settings. Patients who harbor it are typically isolated from other CF patients—separate clinic days, rooms, and spirometers per institutional policy. A missed identification is an outbreak waiting to happen.
Cepacia syndrome. A subset of patients progress to rapidly fatal necrotizing pneumonia and bacteremia. That risk, plus intrinsic resistance to many antipseudomonal agents, is why the selective-agar hunt is not optional.
The complex is often oxidase variable, can grow on MacConkey, and may oxidize lactose or maltose. It is not S. maltophilia and not P. aeruginosa . If MALDI or biochemicals are equivocal, do not issue a casual “Pseudomonas species” report on a CF patient without completing the Burkholderia workup.
Slow growers and small-colony variants
S. aureus small-colony variants (SCVs) are tiny, often nonhemolytic or weakly hemolytic colonies that can look like coagulase-negative staphylococci or even coryneforms. Many are auxotrophic for hemin, menadione, or thymidine and persist intracellularly. They are associated with chronic CF infection and with patients who have received long-term antibiotics (including trimethoprim-sulfamethoxazole or aminoglycosides). Hold plates, use MSA, and pick pinpoint catalase-positive cocci. A 24-hour blood-agar glance will miss them.
B. cepacia complex and some Haemophilus isolates can also be slow. A CF culture signed out at 24 hours with “normal flora and Pseudomonas” is not finished.
Do not let swarming Proteus or mucoid Pseudomonas hide Haemophilus
This is a technique item, not trivia. Proteus swarming can veil an entire blood agar plate. Mucoid P. aeruginosa can bury pinpoint Haemophilus on chocolate. The M-level workup:
Include chocolate agar on every CF and lower-tract pathogen hunt that must recover H. influenzae .
Place a bacitracin disk on chocolate to suppress competing Gram-positive flora and create a readable zone.
Use CNA or PEA if needed to recover Gram-positive pathogens from a swarm, and MacConkey or CLED-type inhibition to see Gram-negatives without swarming.
Subculture under and around mucoid colonies rather than assuming the mucoid organism is the only isolate.
Incubate chocolate in CO2 and hold it; Haemophilus is not a 12-hour organism in a Pseudomonas swamp.
Quantitative reporting and CF workup share a theme: the organism that kills the patient may not be the prettiest colony. Counts tell you whether a BAL isolate is likely pneumonia. Selective media and a skeptical eye tell you whether H. influenzae , an SCV, or B. cepacia complex is hiding under alginate. Laboratories follow validated procedures for both the math and the media—but the outline expects you to know why those procedures exist.